importance. The relative importance of hemodynamic and embolic factors in patients with complete CA occlusion remains unclear. 3, 8, 17, 23 These patients may suffer stroke from hemodynamic insufficiency distal to the CA occlusion or from emboli arising from several sources, including the stump of the occluded ICA in the neck, the tail of the thrombus that forms distal to the occlusion, and the contralateral CA. Treatment with antithrombolytic drugs such as aspirin or warfarin is not likely to prevent hemodynamic stroke. Surgical revascularization procedures have the potential to prevent hemodynamic cerebral infarction.
A variety of indirect methods for evaluating the status of the distal cerebral vasculature have been developed to understand better the effects of proximal atherosclerotic lesions and collateral circulation on cerebral hemodynamics. The rationale for these methods is based on the compensatory responses made by the brain to progressive reductions in CPP. A fairly uniform value for the ratio between CBF and cerebral metabolism exists in all areas of the brain. Because of the resting balance between flow and metabolism, the cerebral OEF from the blood shows little regional variation. The actual value for OEF varies in individuals and from measurement to measurement within the same person, but it is approximately one third for normal individuals. 12, 17, 25, 29 Changes in CPP over a wide range have little effect on CBF. 20, 33 Increases in mean arterial pressure produce vasoconstriction of pial arterioles, and decreases produce vasodilation, thus altering resistance and maintaining a constant CBF. This phenomenon is known as autoregulation. These changes are accompanied by corresponding changes in intravascular CBV, with CBV increasing as CPP is reduced. 18 Autoregulation fails when the capacity for compensatory vasodilation has been exceeded and CBF begins to decline. Evaluation of measurements of arteriovenous O 2 differences obtained in animals and humans has underscored the brain's capacity to increase the OEF when O 2 supply is diminished due to decreasing CBF. 10, 11, 22, 26 Cerebral O 2 metabolism is now maintained by a progressive increase in OEF. Once this mechanism becomes maximal, further declines in blood flow cause disruption of normal cellular metabolism, and infarction may result.
Three basic strategies have been used to assess regional CPP in humans based on knowledge of the normal compensatory responses of the brain. In recently ischemic or infarcted brain tissue, CBF, CBV, CMRO 2 , and cerebrovascular reactivity can be profoundly changed in a complex manner. The first strategy entails using paired rCBF measurements, with the initial measurement obtained at rest and the second measurement obtained after provision of a cerebral vasodilatory stimulus. Induction of hypercapnia, administration of acetazolamide, and physiological tasks such as hand movement have been used as vasodilatory stimuli. Normally, each results in a robust increase in CBF. If the CBF response is muted or absent, preexisting autoregulatory cerebral vasodilation caused by reduced CPP is inferred. A second strategy involves either the measurement of rCBV alone or in combination with measurements of rCBF in the resting brain to detect the presence of autoregulatory vasodilation. The third strategy relies on direct measurements of rOEF to identify patients with increased OEF as a result of impaired cerebral hemodynamics. Combining rOEF measurements with rCBV and rCBF measurements increases the information available to allow for accurate assessment of cerebral hemodynamics. 13, 17, 30, 32, 36 Positron emission tomography measurements of rCBF, rCBV, and rOEF have been used to classify changes in regional cerebral hemodynamics into three stages. 32 Regional CBV, the rCBV/rCBF ratio, and rOEF are all normal at normal levels of CPP (Stage 0). At milder levels of CPP reduction, the cerebral resistance vessels dilate to maintain CBF. Regional CBF is normal or mildly reduced (depending on metabolic demand), rCBV is elevated, and rOEF remains at normal levels (Stage 1). If CPP decreases to lower levels, the capacity of the cerebral resistance vessels to dilate and maintain blood flow is exceeded, and rCBF begins to decline. Regional CBV, the rCBV/rCBF ratio, and rOEF all increase. The ability of the brain to increase the extraction of O 2 from the blood, which is reflected by the increased rOEF, enables the brain to maintain O 2 use at normal levels (Stage 2), which reflects a more severe decrease in CPP (Fig. 1) .
The impact of cerebral hemodynamics on the pathogenesis and treatment of stroke has been assessed using several different methodologies. 8, 23 The strongest evidence for an association between cerebral hemodynamic impairment and stroke has been provided by the SLCOS. 16 This was a blinded prospective study conducted to test the hypothesis that Stage 2 hemodynamic failure (increased OEF) in the cerebral hemisphere distal to complete CA occlusion was an independent predictor of the subsequent risk of stroke in symptomatic medically treated patients. Inclusion criteria were occlusion of one or both common CAs or ICAs as demonstrated by angiography or MR angiography in patients with transient ischemic neurological deficits (including transient monocular blindness) or mild-to-moderate neurological deficits (stroke) in the territory of the occluded CA. Positron emission tomography measurements of CBF, CBV, CMRO 2 , and OEF were undertaken. Patients with left-to-right OEF ratios in the MCA territory outside the normal range were categorized as having Stage 2 hemodynamic compromise in the cerebral hemisphere with higher OEF. These categorizations were made without knowledge of the side of the CA occlusion or of the clinical course after the initial PET study was obtained. No information regarding the results of PET scanning was provided to the patients, treating physicians, or investigator responsible for determining endpoints. The primary endpoint was subsequent ischemic stroke, defined clinically as a neurological deficit of presumed ischemic cerebrovascular cause lasting longer than 24 hours in any cerebrovascular territory. Secondary endpoints were ipsilateral ischemic stroke and death. All living patients were followed for the duration of the study. Patients were divided into two groups: those with stage 2 hemodynamic compromise ( Fig. 1 ) and those with normal (symmetrical) OEF. Comparison of 17 baseline risk factors and subsequent medical treatment between the two groups was performed. Successful initial data collection and PET measurement were performed in 81 patients who were enrolled in the study. State 2 hemodynamic failure (increased OEF) in one hemisphere was documented in 39 patients, and no such failure was found in 42. In all 39 patients with Stage 2 hemodynamic failure, the hemisphere with increased OEF was ipsilateral to the occluded CA. There were no significant differences between the two groups in baseline risk factors or subsequent medical treatment. Arteriographic demonstration of the collateral circulation did not permit differentiation between the two groups.
The mean follow-up duration of the patients was 31.5 months. Fifteen total and 13 ipsilateral ischemic strokes occurred during the follow-up period. There were no hemorrhages. In the 39 Stage 2 patients, 12 total and 11 ipsilateral strokes occurred. In the 42 patients with normal OEF, there were three total and two ipsilateral strokes. The Kaplan-Meier estimates for the risk of subsequent stroke at 1 and 2 years are given in Table 1 . The risk of all ischemic strokes in symptomatic Stage 2 patients was significantly higher than that in those with normal OEF (p = 0.005 and p = 0.004, respectively). Twelve deaths occurred during the follow-up period. Ten deaths were caused by nonstroke-related factors, and two deaths resulted from large cerebral infarctions ipsilateral to a symptomatic occluded ICA. Both stroke-related deaths occurred in patients with increased OEF. There were six deaths in each group. No significant difference in the risk of mortality was demonstrated (p = 0.942). In the univariate analysis of the relation between patient characteristics and subsequent medical treatment, only younger age and Stage 2 hemodynamic failure were significant predictors of all strokes. Both variables remained significant in the multivariate analysis.
Investigators in a Japanese study also demonstrated that PET measurements of OEF can predict subsequent stroke in patients with symptomatic cerebrovascular disease. Yamauchi and coworkers performed PET measurements in 40 medically treated patients with symptomatic occlusion or intracranial stenosis of the ICA or MCA systems. 39, 40 Carotid artery occlusion was demonstrated in 30 patients. Cases were divided into two categories based on the mean hemispheric value of OEF in the symptomatic cerebral hemisphere. Seven patients with OEF greater than 53.3% (the 95% confidence intervals obtained in 10 healthy individuals) were considered to have increased OEF; the remaining 33 were considered to have normal OEF. At 1 year after the PET studies, stroke had developed in five of seven patients with increased OEF. Four strokes were ipsilateral and one was contralateral. A stroke occurred in four of 33 patients with normal OEF; two strokes were ipsilateral and two were contralateral. After the 1st year of follow up, one ipsilateral stroke and one contralateral stroke occurred, both in patients with normal OEF. This corresponds to a 2-year ipsilateral stroke rate of 57% in the high OEF group and 15% in the normal OEF group. This difference was significant for total (p = 0.0002) and
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The Carotid Occlusion Surgery Study ipsilateral stroke (p = 0.002). Multivariate analysis revealed that absolute OEF and recurrent symptoms were the only significant independent predictors of subsequent stroke.
In several laboratories PET has been used to demonstrate postoperative improvement of cerebral hemodynamics after STA-MCA bypass. 4, 5, 14, 21, 24, 30, 31, 34 In patients with Stage 2 hemodynamic failure (increased OEF), EC-IC bypass returns hemispheric OEF ratios to normal. 14, 15, 30, 34 All these studies provided retrospective analyses of surgery-treated patients. No prospective analysis of patients with occlusion of the ICA and increased O 2 extraction randomized to medical treatment or EC-IC bypass has been conducted. The long-term benefit of using impaired cerebral hemodynamics in the selection of patients for EC-IC bypass to prevent stroke thus remains unproven at this time.
The results of medical treatment of Stage 2 patients in the SLCOS were poor and comparable with those reported for medically treated patients harboring symptomatic severe CA stenosis. 27 Surgical procedures that improve cerebral hemodynamics such as EC-IC bypass surgery would be a logical treatment for these patients. In the absence of an empirical trial, however, it cannot be assumed that the morbidity and mortality attendant on surgery would be outweighed by any subsequent reduction in stroke risk. The large multicenter randomized trial of EC-IC bypass surgery conducted between 1977 and 1985 showed no benefit of surgery related to preventing subsequent stroke. 9 At the time that this trial was conducted, there was no reliable and proven method for identifying a subgroup of patients in whom cerebral hemodynamic factors were of primary pathophysiological importance. It has been established that such a subgroup can be identified and, furthermore, that they are at high risk for subsequent stroke when treated only medically. It is appropriate to perform a new trial of EC-IC bypass surgery restricted to patients with symptomatic CA occlusion and Stage 2 (increased OEF) impairment of cerebral hemodynamics.
THE COSS
The goal of the trial is to test the hypothesis that STA-MCA anastomosis, when combined with the best medical therapy, can be reduced by 40%, despite perioperative stroke and death, subsequent ipsilateral ischemic stroke (fatal and nonfatal) at 2 years in patients with recent (Յ 120-day) symptomatic ICA occlusion and ipsilateral increased OEF measured by PET. The hypothesis will be tested by conducting a nonblinded, controlled trial in 372 patients randomized equally to surgical or nonsurgical treatment. Only patients with impaired hemodynamics in the cerebral hemisphere ipsilateral to the CA occlusion will be randomized.
Before proposing a PET-based clinical trial based to select patients with symptomatic CA occlusion for EC-IC bypass, a thorough examination of cost effectiveness was performed.
7 A Markov chain model was created to compare the costs and effectiveness of medical treatment alone with PET screening followed by EC-IC bypass (if OEF was elevated) in patients with symptomatic CA occlusion. The incremental costs per incremental QALY gained were calculated. The cohort used in this analysis consisted of a high-risk group of 45 patients with increased OEF and recent (within 120 days) symptoms of cerebral hemispheric ischemia identified by retrospective subgroup analysis from the STLCOS. In the base-case analysis, the count-based OEF threshold determined a priori from the range of normal values was used. In subsequent analyses, different OEF thresholds were evaluated to identify the optimal one in terms of cost effectiveness. Based on this analysis, it was believed that screening of patients with CA occlusion who exhibited hemispheric symptoms within 120 days and, in those with increased OEF, who then underwent EC-IC bypass would prolong quality-adjusted survival by 50 QALYs/10 years/100 patients at a cost of $19,600 per QALYs gained compared with medical therapy alone. This cost per QALY is considered to be highly cost effective. A more specific OEF threshold determined from post hoc data analysis identified a very high-risk group, resulting in a gain of 49 QALYs/10 yrs/100 patients at a cost savings of $11,000 per patient. This more specific OEF threshold was used in the design of the COSS.
The major patient inclusion criteria include the following. 1) A TIA or mild-to-moderate permanent ischemic neurological deficit (modified Barthel Index Ն 12/20) in the hemispheric CA territory appropriate to the occluded CA (within 120 days prior to PET). 2) Increased OEF in the symptomatic cerebral hemisphere ipsilateral to the occluded CA (PET O 15 O/H 2 15 O count-based ratio image with ipsilateral-to-contralateral OEF ratio Ͼ 1.13) (Fig.  1). 3) Intraarterial arteriography demonstrating the following: occlusion of one ICA; less than 50% stenosis of the contralateral extracranial ICA; and extra-and intracranial vessels suitable for STA-MCA anastomosis.
Eligibility for PET scanning will be based on fulfillment of clinical entry criteria and the presence of unilateral CA occlusion with less than 50% contralateral extracranial ICA stenosis evidenced on Doppler ultrasonography, MR angiography, computerized tomography angiography, or intraarterial arteriography. If PET scanning demonstrates findings consistent with criteria for ipsilateral increased oxygen extraction, then arteriographic criteria must be met prior to randomization. Thus, intraarterial arteriography is required prior to randomization to document CA occlusion, less than 50% contralateral extracranial ICA stenosis and both extracranial and intracranial arteries suitable for anastomosis. Prior to PET scanning, a decision will be made whether supplemental arteriogra- phy will be necessary either because it has not been performed or because the existing study is inadequate to provide the necessary information. Supplemental arteriography will be undertaken as part of COSS only if the PET study meets criteria for increased OEF. After consent is obtained, all patients will be instructed to take aspirin (81-325 mg per day) and to discontinue the use of any other antithrombolytic therapy (specifically oral anticoagulant agents, ticlopidine, clopidogrel and dipyridamole) until the 30 to 40-day follow-up visit. After this time, the need for antithrombolytic therapy will be determined by the physicians caring for the patient. Patients randomized to surgery will undergo STA-MCA bypass as soon as possible. Standard surgical techniques for anastomosis of one branch to a cortical branch of the MCA will be used. All randomized patients will receive the best available medical treatment with antithrombolytic agents and risk-factor intervention to prevent subsequent stroke. All surgery-treated patients will be seen 30 to 40 days postoperatively. Patients not undergoing surgery will be seen 40 to 50 days after randomization. All surgery-treated patients will undergo PET scanning 30 to 40 days after surgery to document reversal of hemodynamic abnormalities. All individuals will be seen at 3-month intervals for the duration of the study.
Primary outcome will be based on the occurrence of ipsilateral ischemic stroke within 2 years of randomization. In the bypass group, outcome will be the occurrence of all strokes or death occurring between randomization and a 30-day postoperative time point, as well as the subsequent occurrence of ipsilateral ischemic stroke. For the nonbypass group, outcome will be the occurrence of all strokes or death during the aforementioned period, as well as the subsequent occurrence of ipsilateral ischemic stroke.
Secondary outcomes will also include all stroke, disabling stroke, fatal stroke, death, Rankin Scale score, National Institutes of Health Stroke Scale score, modified Barthel Index, and Stroke Specific Quality of Life Assessment.
The initial design of the study requires enrollment of 930 clinically eligible patients for PET scanning-yield 372 patients with increased OEF for randomization, half to surgery and half to nonsurgerical therapy. Given our current estimates of the primary event rates, this will yield 90% power for a 5% level two-sided test to detect a 40% decrease in the rate of the primary outcome in favor of the surgery arm.
CONCLUSIONS
Increased OEF (Stage II hemodynamic failure) measured by PET scanning is a powerful, independent risk factor for subsequent ipsilateral stroke with symptomatic complete occlusion of the ICA. An STA-MCA anastomosis can restore OEF to normal level in patients with ICA occlusion. The COSS will test the hypothesis that STA-MCA anastomosis when combined with the best medical therapy can reduce by 40% subsequent ipsilateral ischemic stroke at 2 years in patients with symptomatic ICA occlusion and Stage II hemodynamic failure occurring with 120 days.
Appendix I
Inclusion and Exclusion Criteria A)Inclusion criteria 1) Vascular imaging studies demonstrating occlusion of one ICA.
2) Vascular imaging studies demonstrating less than 50% stenosis of the contralateral extracranial ICA.
(Note: The two aforementioned inclusion criteria may be demonstrated using any vascular imaging modality (that is, Doppler ultrasonography, MR angiography, computerized tomography angiography or intraarterial arteriography. Additionally, validation of sensitivity and specificity of nonarteriographic modalities compared with arteriography is not required because all participants must have undergone catheter arteriography to determine final eligibility.)
3) A TIA or ischemic stroke in the hemispheric CA territory of the occluded CA.
a) This is a clinical diagnosis based on all available data not requiring confirmation by neuroimaging. Patients with TIA or infarction restricted to the retina only are not eligible, but those with combined retinal and hemispheric CA territory syndromes will be eligible. In patients with hemisensory or hemimotor signs or symptoms, including a single limb, specific hemispheric signs or symptoms (for example, aphasia) will not be required for inclusion, but absence of cerebellar and brainstem signs or symptoms will be required. B) Exclusion criteria 1) Nonatherosclerotic CA disease. (The intent is to include only those with atherosclerotic CA occlusion. All other nonatherosclerotic conditions (for example, moyamoya disease, fibromuscular dysplasia, CA dissection, arteritis, radiation-induced vasculopathy such as that occurring after irradiation for neck cancer) are excluded. These entities are given as examples, and not as an allinclusive list.)
2) Blood dyscrasias including the following conditions only: polycythemia vera; essential thrombocytosis; and sickle cell disease. (This is an all-inclusive list. The following conditions are not exclusions: anticardiolipin antibodies, lupus anticoagulant, proteins S or C deficiency, antithrombin III deficiency, Factor V Leiden or other causes of activated protein C resistance, and prothrombin gene mutations.)
3) Known heart disease likely to cause cerebral ischemia (echocardiography is not required) including the following conditions only: atrial fibrillation, prosthetic valve(s), infective endocarditis, left atrial or ventricular thrombus, sick sinus syndrome, myxoma, and cardiomyopathy with ejection fraction less than 25%.
(This is an all-inclusive list. The following conditions are not exclusions: patent foramen ovale or atrial septal aneurysm.) 4) Other nonatherosclerotic conditions likely to cause focal cerebral ischemia.
5) The following medical conditions: cancer (other than skin), renal failure (blood urea nitrogen and/or creatinine Ͼ twice normal upper limit), congestive heart failure, myocardial infarction within 6 months, liver disease, and pulmonary disease constituting an anesthetic risk.
6) Any condition likely to lead to death within 2 years.
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The Carotid Occlusion Surgery Study 7) Other neurological disease that would confound followup assessment. 8) Pregnancy. 9) Subsequent planned cerebrovascular surgery that might alter cerebral hemodynamics or stroke risk. (This includes contralateral internal or common carotid endarterectomy or angioplasty, ipsilateral external CA endarterectomy or angioplasty, CA stump closure, vertebral or basilar artery angioplasty, any arterial grafting procedures to the CA or vertebral arteries.) 10) Any condition that in the participating surgeon's judgment makes the patient an unsuitable surgical candidate.
11) Concurrent participation in any other experimental treatment trial.
12) Participation within the previous 12 months in any experimental study that included exposure to ionizing radiation.
13) Acute, progressing, or unstable neurological deficit (neurological deficit must be stable for 72 hours prior to of PET scanning).
14) Allergy to iodine or radiographic contrast media if supplemental arteriography is required.
15) Allergy to aspirin. 16) Medical indication for treatment with anticoagulant drugs, ticlopidine, clopidogrel, or dipyridamole such that these medications cannot be replaced with aspirin for 1 month after enrollment. (Note: patients with any of the medical conditions specified in exclusion Criteria 17 through 20 can become eligible if the exclusion criterion no longer applies within 120 days of onset of the most recent qualifying event.) 17) Uncontrolled diabetes mellitus (fasting blood glucose Ͼ 300 mg%/16.7 mmol/l).
18) Uncontrolled hypertension (systolic BP Ͼ 180, diastolic BP Ͼ 110).
19) Uncontrolled hypotension (diastolic BP Ͻ 65). 20) Unstable angina.
